Clinical trials: Plasma Cell Neoplasm
Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
Bryostatin and Vincristine in B-Cell Malignancies
This phase I trial is studying the side effects and best dose of bryostatin-1 when given together with vincristine in treating patients with chronic lymphocytic leukemia, non-Hodgkin's lymphoma, or multiple myeloma.
- Conditions
- Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma
- Trial name
- NCT00003166
- Testing
- bryostatin 1, vincristine sulfate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
This Phase I/IIa clinical study is to test safety and anti-tumor activity of BT062 to define the best dose in treating patients with relapsed or refractory multiple myeloma with multiple doses of BT062.
- Trial name
- NCT01001442
- Testing
- BT062
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- Biotest Pharmaceuticals Corporation
Chronic Myeloproliferative Disorders, Leukemia
Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases
RATIONALE: Listening to relaxing music during a bone marrow biopsy may be effective in reducing anxiety and pain. PURPOSE: This randomized clinical trial is studying how well music works in reducing anxiety and pain in adult…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT00376922
- Testing
- music therapy
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Wake Forest University Health Sciences
AL Amyloidosis (AL), Cardiac Amyloidosis
Multimodal Radiomics Model (18F-FAPI PET/CT + CMR) for AL Cardiac Amyloidosis Prognosis
1. Goal of the Study: The goal of this prospective observational study is to develop and validate a novel, non-invasive method for predicting the prognosis of patients with light-chain cardiac amyloidosis (AL-CA).
- Trial name
- AL-CA (NCT07103863)
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Beijing Anzhen Hospital
Lymphoma, Leukemia
Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies
This study investigates the efficacy and safety of direct oral anticoagulants (DOACs) in comparison with standard low-molecular-weight heparin (LMWH) for the prevention of venous thromboembolism in patients with hematological…
- Conditions
- Lymphoma, Leukemia, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Venous Thromboembolic Disease
- Trial name
- HEM-DOAC (NCT07270263)
- Testing
- Apixaban, Rivaroxaban, low molecular weight heparin (enoxaparin sodium)
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Gdansk
Hematological Malignancies
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the efficacy of teclistamab at the recommended Phase 2 dose (RP2D).
- Trial name
- MajesTEC-1 (NCT04557098)
- Testing
- Teclistamab
- Where
- 51 sites in United States, Belgium and 9 more
- Volunteers
- 194 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
Daratumumab Provided at Home Experience An Open, Single-center, Mixed-method Project.
Multiple myeloma (MM) is the second most common hematological disease in Denmark with an incidence of approximately 350 diagnosed cases per year.
- Trial name
- NCT05306587
- Testing
- Darzalex
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Thomas Lund
Leukemia, Lymphoma
T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer
RATIONALE: Giving chemotherapy, such as fludarabine and cyclophosphamide, and total-body irradiation before a donor umbilical cord blood transplant helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm
- Trial name
- NCT00602693
- Testing
- umbilical cord blood transplantation, Allopurinol, fludarabine phosphate
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Multiple Myeloma
Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib
The objective of this study is to describe the effect of optimized retreatment with bortezomib in combination with dexamethasone followed by prolonged therapy with bortezomib, versus standard retreatment with bortezomib in…
- Trial name
- OPTIMRETREAT (NCT01910987)
- Testing
- bortezomib (optimized retreatment), dexamethasone (optimized retreatment), bortezomib (standard retreatment)
- Where
- 54 sites in Belgium, Finland and 9 more
- Volunteers
- 80 people
- Sponsor
- Janssen-Cilag International NV
Multiple Myeloma, Relapse
Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
This research study aims to evaluate the safety and effectiveness of the combination of isatuximab, pomalidomide, and dexamethasone (Isa-Pd) for the treatment of relapsed or refractory multiple myeloma (RRMM), which refers to…
- Conditions
- Multiple Myeloma, Relapse, Refractory, Aging
- Trial name
- NCT05911321
- Testing
- Isatuximab, Pomalidomide, Dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Multiple Myeloma
A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma
The purpose of Phase 1b of the study is to determine the maximum tolerated dose (MTD) of oprozomib in combination with melphalan and prednisone (OMP).
- Trial name
- NCT02072863
- Testing
- Oprozomib, Melphalan, Prednisone
- Where
- 8 sites in Greece, Italy and 1 more
- Volunteers
- 9 people
- Sponsor
- Amgen
Multiple Myeloma
An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments
Belantamab mafodotin (GSK2857916) is a first in class, antibody dependent cellular cytotoxicity (ADCC) enhanced, humanized immunoglobulin G1 (IgG1) antibody-drug conjugate (ADC) which binds specifically to B cell maturation…
- Trial name
- NCT03828292
- Testing
- Belantamab mafodotin, Bortezomib, Dexamethasone
- Where
- 4 sites in Japan
- Volunteers
- 15 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
Study of ZIO-101 in Multiple Myeloma
The study of safety of a new organic arsenic compound in the treatment of advanced multiple myeloma
- Trial name
- NCT00303199
- Testing
- ZIO-101 (Darinaparsin)
- Where
- 8 sites in United States, Canada
- Volunteers
- 35 people
- Sponsor
- Alaunos Therapeutics
Multiple Myeloma and Plasma Cell Neoplasm
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003399
- Testing
- carmustine, cisplatin, cyclophosphamide
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
Multiple Myeloma
Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM)
An Open Label, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of SDX-101 (R-Etodolac) in Patients with Relapsed or Refractory Multiple Myeloma (MM)
- Trial name
- NCT00293111
- Testing
- SDX-101 (R-Etodolac)
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Cephalon
Plasma Cell Dyscrasia, Monoclonal Gammopathy
A Diagnostic Screening Trial Seeking AL Amyloidosis Very Early
This protocol seeks to enroll smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significant (MGUS) patients with λ light chain (LC) involvement, a group of patients for whom standard of care is…
- Trial name
- SAVE (NCT02741999)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Tufts Medical Center
Multiple Myeloma and Plasma Cell Neoplasm
Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.
- Trial name
- NCT00618345
- Testing
- everolimus, DNA analysis, protein analysis
- Volunteers
- 35 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
RATIONALE: Thalidomide may stop the growth of cancer cells by stopping blood flow to the cancer. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00040937
- Testing
- filgrastim, sargramostim, cyclophosphamide
- Where
- 141 sites in United States
- Volunteers
- 147 people
- Sponsor
- SWOG Cancer Research Network
Multiple Myeloma
Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone
Evaluation of the effect iberdomide combined with low-dose cyclophosphamide and dexamethasone in patients with relapsed/refractory multiple myeloma.
- Trial name
- ICON (NCT04392037)
- Testing
- Iberdomide plus low-dose cyclophosphamide and dexamethasone
- Where
- 9 sites in Netherlands
- Volunteers
- 60 people
- Sponsor
- Amsterdam UMC, location VUmc
Waldenstrom Macroglobulinemia
Spanish Registry of Patients With IgM Monoclonal Gammopathies
Waldenström's macroglobulinemia (WM) is a B-cell lymphoproliferative disorder which is defined by bone marrow infiltration by small lymphocytes, lymphoplasmacytoid and plasma cells together with the presence of a detectable…
- Trial name
- PRAME (NCT05093153)
- Where
- 51 sites in Spain
- Volunteers
- 1,000 people
- Sponsor
- Fundación Española de Hematología y Hemoterapía